Skip to content

Advertisement

  • Poster presentation
  • Open Access

Fusion inhibitors and their evolving role during salvage antiretroviral therapy. Seven years of experience with enfuvirtide

Retrovirology20107 (Suppl 1) :P52

https://doi.org/10.1186/1742-4690-7-S1-P52

  • Published:

Keywords

  • Site Injection Reaction
  • Darunavir
  • Raltegravir
  • Maraviroc
  • Etravirine

Background

The need of rescue antiretroviral regimens is progressively increasing, due to the unavoidable long-term emerging of multiresistant HIV strains.

Methods

An open-label study featuring the administration of the fusion inhibitor enfuvirtide (T-20) as a part of salvage anti-HIV regimens in a cohort of hardly pre-treated and multiresistant patients (p) with advanced HIV disease, followed until at least three consecutive years, is presented.

Results

The efficacy and safety parameters of enfuvirtide adjunct to an optimized background were assessed monthly in 21 severely compromised p, with a baseline viremia ranging from 64,000 to over 500,000 HIV-RNA copies/mL, and a CD4+ lymphocyte count ranging from 11 to 213 cells/μL. At the time of enfuvirtide introduction, the background antiretroviral therapy was modified according to both genotypic-virtual phenotypic resistance assays, but only 15 of 21 p could rely on at least one in vitro effective drug (during the first years of our experience, raltegravir, maraviroc, etravirine, riplpivirine, and also tipranavir and darunavir were not still available). Anyway, a rapid and significant drop of viremia (at least one Log10 HIV-RNA copies/mL), associated with a 30-280% increase of CD4+ cell count versus baseline values was observed in all p, although 13 our of 15 p who could rely on an optimized background had a sustained response (12-36 months). In 11 p, a surprising dissociation between a favorable virological response and a progressive loss of CD4+ cells was observed. Although frequent, local injection site adverse effects never represented the major cause of enfuvirtide interruption.

Discussion

Expectations and concerns on the use of enfuvirtide as a novel anti-HIV compound in daily practice are still debated, since no specific recommendations have been produced (especially with regard with the novel, available compounds), when excluding the assumption that enfuvirtide appears significantly more effective when administered concurrently with at least 1-2 other active antiretrovirals, although the reported experiences often included p on very advanced salvage therapies. The management of the frequent site injection reactions represents an adjunctive concern for these multi-problematic HIV-infected p.

Authors’ Affiliations

(1)
Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy

Copyright

© Manfredi; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement